Tech Company Financing Transactions
Apexigen Funding Round
On 8/10/2018, Apexigen raised $15 million in Series B funding from Decheng Capital and private investors.
Transaction Overview
Company Name
Announced On
8/10/2018
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series B
Investors
Decheng Capital (Lead Investor)
Proceeds Purpose
Apexigen intends to use these proceeds to advance the clinical development of its lead immuno-oncology (I-O) therapeutic APX005M, a monoclonal antibody targeting CD40.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
75 Shoreway Rd. C
Burlingame, CA 94070
USA
Burlingame, CA 94070
USA
Phone
Website
Email Address
Overview
Apexigen is a biopharmaceutical product development company developing products to address life-threatening and difficult to treat diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Xiaodong Yang
Chief Financial Officer
Linda Rubinstein
Chief Medical Officer
Ovid Trifan
Vice President
Rena Bahjat
Vice President
Thomas Jahn
Vice President
Jason Wright
VP - Bus. Development
Mark Nevins
VP - Finance
Amy Wong
Browse more venture capital transactions:
Prev: 8/10/2018: Datasembly venture capital transaction
Next: 8/10/2018: Root AI venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on tech company VC transactions. VC transactions reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs